MARKET

SPRO

SPRO

Spero
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.27
-0.50
-4.25%
After Hours: 11.27 0 0.00% 16:00 09/23 EDT
OPEN
11.74
PREV CLOSE
11.77
HIGH
11.81
LOW
11.06
VOLUME
53.02K
TURNOVER
--
52 WEEK HIGH
14.48
52 WEEK LOW
5.52
MARKET CAP
210.26M
P/E (TTM)
-5.0434
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SPRO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SPRO News

  • Benzinga's Top Upgrades, Downgrades For September 9, 2019
  • Benzinga.09/09 13:59
  • Morgan Stanley sees 23% upside in Galapagos in premarket analyst action
  • Seeking Alpha - Article.09/09 12:51
  • Janney Capital Initiates Coverage On Spero Therapeutics with Buy Rating
  • Benzinga.09/09 10:45
  • Spero Therapeutics started at buy with $27 stock fair value estimate at Janney
  • marketwatch.com.09/09 09:29

More

Industry

Biotechnology & Medical Research
-0.69%
Pharmaceuticals & Medical Research
-0.44%

Hot Stocks

Name
Price
%Change

About SPRO

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.
More

Webull offers Spero Therapeutics Inc (SPRO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.